Jan 09, 2023 / 10:15PM GMT
Lut Ming Cheng - JPMorgan Chase & Co, Research Division - Research Analyst
Good afternoon. Thanks for joining us for another session at our 41st Annual JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts covering Roivant Sciences at the firm. Presenting next is the management team for Roivant. (Operator Instructions) Pass the stage to Roivant's CEO, Mat Gline for the presentation. Matt, welcome, and the stage is yours.
Matthew Gline - Roivant Sciences Ltd. - CEO & Director
Thank you, Brian. Good afternoon, everybody. Thank you for coming. Excited to present and then take some questions, and yes, looking forward to it. So we're going to make some forward-looking statements for more information. You can consult our forward-looking statements and disclaimers.
So I'm going to start on Page 3 for those following along online. I'm not going to spend a ton of time on the past, but I just want to reflect, 2022 has actually been a very busy year for us. We launched our first wholly owned product in VTAMA, which got
Roivant Sciences Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers